Stephen Michael Kelsey - 11 Sep 2025 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
President, Research and Development
Signature
/s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey
Issuer symbol
RVMD
Transactions as of
11 Sep 2025
Net transactions value
-$4,966,504
Form type
4
Filing time
15 Sep 2025, 20:51:43 UTC
Previous filing
18 Jun 2025
Next filing
18 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kelsey Stephen Michael President, Research and Development C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY /s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey 15 Sep 2025 0001462808

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Options Exercise $473,000 +100,000 +35% $4.73 389,414 11 Sep 2025 Direct F1, F2
transaction RVMD Common Stock Sale $1,919,963 -44,059 -11% $43.58 345,355 11 Sep 2025 Direct F1, F2, F3
transaction RVMD Common Stock Sale $2,488,519 -55,941 -16% $44.48 289,414 11 Sep 2025 Direct F1, F2, F4
transaction RVMD Common Stock Options Exercise $118,250 +25,000 +8.6% $4.73 314,414 15 Sep 2025 Direct F1, F2
transaction RVMD Common Stock Sale $1,087,418 -23,682 -7.5% $45.92 290,732 15 Sep 2025 Direct F1, F2, F5
transaction RVMD Common Stock Sale $61,854 -1,318 -0.45% $46.93 289,414 15 Sep 2025 Direct F1, F2, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -100,000 -64% $0.000000 55,055 11 Sep 2025 Common Stock 100,000 $4.73 Direct F1
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -25,000 -45% $0.000000 30,055 15 Sep 2025 Common Stock 25,000 $4.73 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025.
F2 Includes 94,426 restricted stock units.
F3 The transaction was executed in multiple trades in prices ranging from $43.12 to $44.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4 The transaction was executed in multiple trades in prices ranging from $44.12 to $44.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F5 The transaction was executed in multiple trades in prices ranging from $45.4650 to $46.46, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F6 The transaction was executed in multiple trades in prices ranging from $46.5450 to $47.21, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

President, Research and Development